Peptidic procollagen C-proteinase inhibitors

Details Peptidic procollagen C-proteinase inhibitors Peptidic procollagen C-proteinase inhibitors

1999-12-10

2002-07-30

Low, Christopher S. F. (Department: 1653)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Tripeptides, e.g., tripeptide thyroliberin , etc.

C530S330000, C514S018700, C514S019300

Reexamination Certificate

active

06426402

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to compounds that inhibit procollagen C-proteinase, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.
BACKGROUND INFORMATION AND RELATED DISCLOSURES
The collagens are integral components of connective tissue. At present nineteen types of collagens have been identified. The interstitial collagen types I, II and III are the major collagen components of tissue. These collagens are synthesized as procollagen precusor molecules having amino- and carboxy-terminal peptide extensions also known as pro-regions. These pro-regions are typically cleaved upon secretion of the procollagen molecule to give a mature collagen molecule which is capable of association into highly structured collagen fibers. (see, e.g., Fessler and Fessler,
Annu. Rev. Biochem.
47, 129, (1978); Kivirikko et al.,
Extracellular Matrix Biochemistry
(1984) and Kuhn,
Structure and Function of Collagen Types
(eds Mayne, R and Burgeson, R. E.), Academic Press, Inc., Orlando, Fla. pp 1-42 (1987).
Excessive collagen deposition is associated with a variety of fibrotic diseases such as interstitial pulmonary fibrosis, pericentral fibrosis, Symmers' fibrosis, perimuscular fibrosis, kidney fibrosis, endocardial sclerosis, hepatitis, acute respiratory distress syndrome, arthritis, cystic fibrosis, surgical adhesions, tendon surgery, corneal scarring, scleroderma, chronic allograft rejection, hemodialysis shunt fibrosis and restenosis. These diseases are characterized by excessive deposits of fibrillar interstitial collagens that are resistant to proteolyic degradation thus leading to the symptoms of fibrosis. Therefore, inhibition of the pathological deposition of these collagens should help in the treatment of these diseases.
Recent studies suggest that procollagen C-proteinase is the essential enzyme that catalyzes the cleavage of the C-propeptide of types I, II and III collagens and therefore instrumental in the formation of functional collagen fibers ((see, Fertala et al.,
J. Biol. Chem.,
269, 11584, (1994)). It would therefore be desirable to provide procollagen C-proteinase inhibitors and thereby provide a means of combating diseases mediated by excessive deposition of these collagens. This invention fulfills this and related needs.
SUMMARY OF THE INVENTION
In a first aspect, this invention provides hydroxamic acids selected from the group of compounds represented by Formula (I):
wherein:
R
1
and R
4
are, independently of each other, hydrogen or alkyl;
R
2
is:
(i) cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heterocyclo or heterocycloalkyl; or
ii) -(alkylene)-B
1
—X where B
1
is —O—, —NR
8
—, —S(O)
0-2
, —C═O, —CONR
8
—, —NR
8
CO
2
—, NR
8
SO
2
— or —C(═NR
8
)NR
8
SO
2
— (where R
8
is H or alkyl), and X is cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, or heteroaralkyl; or
(iii) -(alkylene)-B
1
—X where B
1
is —NR
8
CO— (where R
8
is H or alkyl), and X is cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl; or
(iv) R
2
and R
3
form an alkylene or heteroalkylene chain; with the proviso that R
2
does not contain an imidazole group.
R
3
is hydrogen or alkyl;
R
6
is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl;
R
5
is:
(i) hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heterocycloalkyl, heteroalkyl, or -(alkylene)-C(O)—X
1
where X
1
is alkyl, hydroxy, alkoxy, aryl, aralkyl, aryloxy, aralkyloxy, heteroaryl, heteroaryloxy, heteroaralkyloxy or NR′R″ (where R′ and R″ are independently H or alkyl, or R′and R″ form an alkylene chain); or
(ii) R
5
and R
4
form an alkylene chain; or
(iii) R
5
and R
6
form an alkylene chain;
n is 0 or 1;
A is —N(R
10
)—(CH
2
)
m
—CH(R
9
)—C(═O)— wherein:
m is an integer from 0-5 inclusive;
R
9
is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocycloalkyl, heteroalkyl, or -(alkylene)-C(O)—X
1
where X
1
is alkyl, hydroxy, alkoxy, aryl, aralkyl, aryloxy, aralkyloxy, heteroaryl, heteroaryloxy, heteroaralkyloxy or NR′R″ (where R′ and R″ are independently H or alkyl, or R′ and R″ form an alkylene chain); and
R
10
is hydrogen, alkyl, aralkyl or heteroaralkyl;
Z is Y—B
2
wherein:
Y is alkylene or a bond; and
B
2
is —CO—, —OC(O)—,
with the proviso that when R
2
is benzyl then Z is not —OC(O)—;
R
7
is cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl;
or a pharmaceutically acceptable salt, prodrug, or isomer thereof.
In a second aspect, this invention provides a method of treatment of a disease in a mammal treatable by administration of a procollagen C-proteinase inhibitor selected from the group of compounds represented by Formula (I):
In a third aspect, this invention provides pharmaceutical compositions containing a therapeutically effective amount of a compound of Formula (I) or its pharmaceutically acceptable salt and a pharmaceutically acceptable excipient.
In a fourth aspect, this invention provides a method of treating disease by administering to a patient a selective inhibitor of procollagen-C-proteinase.
In a fifth aspect, this invention provides a method of preparing compounds of Formula (I).


REFERENCES:
patent: 0 084941 (1983-08-01), None
patent: 2762315 (1997-04-01), None
patent: 01 146896 (1989-06-01), None
patent: 08311096 (1996-11-01), None
patent: 09 025293 (1997-01-01), None
patent: WO 92/22523 (1992-12-01), None
patent: WO 95/12612 (1995-05-01), None
patent: WO 96/33176 (1996-10-01), None
patent: WO 97/05865 (1997-02-01), None
patent: WO97/43251 (1997-11-01), None
patent: WO97/49679 (1997-12-01), None
patent: WO98/15525 (1998-04-01), None
patent: WO98/22494 (1998-05-01), None
patent: WO 98/55449 (1998-12-01), None
Abstract of JP-09025293-A, 1997.*
Ewenson, et al.,Eur. J. Med. Chem.vol. 27:3, pp 179-186 (1992), Synthesis and biological activity of peptide hydroxamate inhibitors of degradation of substance P analogues.
Chen, et al.,Bioorg. Med. Chem. Lett., vol. 2:12, pp1685-90 (1992), “One-pot synthesis of cathepsin inhibitors: N&agr;-protected N-peptidyl-o-acetyl hydroxylamines catalysed by alcalase followed by lipase in anhydrous t-butanol”.
Nikam, et al.,Tetrahedron Letters, vol. 36:2, pp 197-200 (1995), “Synthesis of hydroxamic acids: Pd/BaSO4 as a new catalyst for the deprotection of o-benzyl hydroxamates”.
Laufer, et al.,Eur. Journal of Biochemistry, vol. 150:1 pp 135-140 (1985), “Inhibition of substance P degradation in rat brain preparations by peptide hydroxamic acids”.
Fischer, et al.,Pharmazie, vol. 38:4, pp 249-250 (1983), “N,O-Diacylhydroxylamines as Enzyme-Activated Inhibitors for Serine Proteases”.
Hoffmann, et al.,Journal of Organic Chemistry; vol. 29: pp 748-751 (1964), “A Peptide Synthesis via Hydroxamic Acids”.
Fertala, et al.,J. Bio. Chem.vol. 269, pp 11584-11589 (1994), Self-assembly into Fibrils of Collagen II by Enzymic Cleavage of Recombinant Collagen II.

Affiliated with

Also associated with

Rating

Peptidic procollagen C-proteinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptidic procollagen C-proteinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptidic procollagen C-proteinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2915623